Next 10 |
home / stock / mrna / mrna articles
On Tuesday, Cathie Wood’s Ark Invest made a significant move by increasing its stake in Moderna Inc. (NASDAQ:MRNA), a leading COVID-19 vaccin...
Tuesday, Moderna Inc (NASDAQ:MRNA) said that mRNA-1283, the company’s next-generation COVID-19 vaccine, has met the primary en...
Ark Investment Management, led by Cathie Wood, continued to buy Tesla Inc. (NASDAQ:TSLA) shares on Monday, even though the stock had already r...
Money manager Cathie Wood’s Ark Invest has a favorite biotech holding now, going by the firm’s recent buying activity. What Happened: A...
On Wednesday, Cathie Wood-led Ark Invest made a significant move by offloading shares of Block Inc (NYSE:SQ) amidst Bitcoin (CRYPTO: BTC) prices re...
Moderna Inc (NASDAQ:MRNA) shares are trading lower by 2.7% to $102.25 during Wednesday’s session in possible sympathy with BioNTech, which re...
On Monday, Cathie Wood-led Ark Invest made significant trades, notably offloading shares of Coinbase Global Inc (NASDAQ:COIN) and Block Inc (NYSE:S...
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 27.41% on an annualized basis producing an average annual return of 40.2...
On Tuesday, Cathie Wood-led Ark Invest made a significant move by offloading a substantial number of shares in Coinbase Global Inc (NASDAQ:COIN), d...
News, Short Squeeze, Breakout and More Instantly...
2024-03-28 09:06:17 ET “Biotech industry has found its footing again”, says Karen Andersen – a Morningstar strategist. Here are the top U.S. based stocks within this space that are particularly worth owning for 2024. Vertex Pharmaceuticals Inc (NASDAQ: VRTX) ...
2024-03-28 09:00:06 ET Michael Yee from Jefferies issued a price target of $125.00 for MRNA on 2024-03-28 07:49:00. The adjusted price target was set to $125.00. At the time of the announcement, MRNA was trading at $110.59. The overall price target consensus is at $173.6...
2024-03-28 07:15:01 ET Goldman Sachs analyst issues BUY recommendation for MRNA on March 28, 2024 05:33AM ET. The previous analyst recommendation was Buy. MRNA was trading at $110.59 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...